Schizophrenia Database

The current version of the database includes clinical safety and efficacy information on both second-generation antipsychotics (SGAs) currently approved or in development for the first-line monotherapy treatment of schizophrenia and on anti-psychotics used for the second-line treatment (monotherapy or add-on) in treatment-resistant or refractory schizophrenia patients. Information on first-generation antipsychotics (FGAs) such as haloperidol are included if they were used as active controls.

A total of 114 references were selected for inclusion in the database, representing clinical outcomes from 114 unique trials, 325 unique treatment arms and about 26,000 patients. Download an information sheet for the Schizophrenia database.